Lombard Odier Asset Management (Europe) LTD Silence Therapeutics PLC Transaction History

Lombard Odier Asset Management (Europe) LTD

$1.57 Billion
Q3 2024

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$17.39 - $26.25 $23.9 Million - $36.1 Million	-1,374,838 Reduced 38.05%	2,238,039 $48.3 Million
Q4 2023 Feb 14, 2024	BUY	$6.7 - $17.67 $1.13 Million - $2.99 Million	168,965 Added 4.91%	3,612,877 $62.8 Million
Q3 2023 Nov 14, 2023	BUY	$5.07 - $10.74 $144,758 - $306,648	28,552 Added 0.84%	3,443,912 $33.8 Million
Q2 2023 Aug 14, 2023	BUY	$4.61 - $7.44 $562,212 - $907,345	121,955 Added 3.7%	3,415,360 $18.8 Million
Q1 2023 May 15, 2023	BUY	$6.2 - $15.61 $466,271 - $1.17 Million	75,205 Added 2.34%	3,293,405 $20.4 Million
Q4 2022 Feb 14, 2023	SELL	$9.69 - $17.09 $11,628 - $20,508	-1,200 Reduced 0.04%	3,218,200 $49.1 Million
Q3 2022 Nov 14, 2022	BUY	$2.65 - $29.85 $8.53 Million - $96.1 Million	3,219,400 New	3,219,400 $32.3 Million
Q2 2022 Aug 15, 2022	SELL	$7.99 - $19.5 $12.5 Million - $30.5 Million	-1,561,551 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$16.5 - $23.89 $25.8 Million - $37.3 Million	1,561,551 New	1,561,551 $29.7 Million

Others Institutions Holding SLN

# of Institutions

Shares Held

28.1M

Call Options Held

300

Put Options Held

Tcg Crossover Management, LLC Palo Alto, CA

3.03M
Shares

$21 Million
7.16% of portfolio
Siren, L.L.C. New York, NY

2.83M
Shares

$19.6 Million
2.57% of portfolio
Lombard Odier Asset Management (Usa) Corp New York, NY

2.66M
Shares

$18.5 Million
3.3% of portfolio
Redmile Group, LLC San Francisco, CA

1.9M
Shares

$13.2 Million
2.26% of portfolio
Frazier Life Sciences Management, L.P. Menlo Park, CA

1.15M
Shares

$7.96 Million
1.12% of portfolio

View Full List

About Silence Therapeutics plc

Ticker SLN
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,888,400
Market Cap $249M
Description
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated...

More about SLN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Lombard Odier Asset Management (Europe) LTD, based on Form 13F filings with the SEC.

News

Stay updated on Lombard Odier Asset Management (Europe) LTD with notifications on news.

Account